Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?

Abstract

AChR-ab levels fell in almost all patients who improved, but also in most patients who did not. Thus, we do not recommend commercially available AChR-ab levels as a biomarker of improvement in MG. However, antibody levels might be useful as a marker for inadequate immunotherapy.